Format

Send to

Choose Destination
Expert Rev Proteomics. 2015;12(6):695-701. doi: 10.1586/14789450.2015.1099436. Epub 2015 Oct 23.

Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone.

Author information

1
a Unit of Medical Statistics, Biometry and Bioinformatics , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.
2
b Laboratory of Proteomics , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.
3
c Biomarkers Unit , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.
4
d Laboratory Medicine , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.
5
e Molecular Targeting Unit , Fondazione IRCCS Istituto Nazionale dei Tumori , Milan , Italy.

Abstract

OBJECTIVE:

Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the plasma levels of hepcidin, interleukin-6 (IL-6), erythropoietin (EPO) and erythroferrone (ERFE) in patients with benign breast disease or cancer.

METHODS:

Plasma samples from a cohort of 131 patients (47 with benign breast disease and 84 with breast cancer) were subjected to the evaluation of hepcidin, IL-6, EPO and ERFE using SELDI-TOF-MS or immunoassays.

RESULTS:

An elevated hepcidin was observed in malignant breast tumors compared to benign ones. No correlation was observed between hepcidin and IL-6, EPO or ERFE.

CONCLUSION:

Since the study included a cohort of patients (87%) with breast cancers smaller than 2 cm, these results may support our previous evidence about the potential role of hepcidin in breast cancer disease.

KEYWORDS:

BMP6; IL-6; benign breast disease; breast cancer; early diagnosis; erytroferrone; erytropoiesis; erytropoietin; hepcidin; inflammation; iron metabolism

PMID:
26496240
DOI:
10.1586/14789450.2015.1099436
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center